News

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible
Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...
CRISPR Therapies Pipeline Outlook Report 2025: Key 25+ Companies And Breakthrough Therapies Shaping The Future Landscape
In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...
The FDA must be modernized for the era of personalized medicine
We need a dedicated framework that clarifies the rules, requirements and incentives for those building personalized ...
Daily News18d
Eric Faw Intellia: Unveiling Powerful Insights and Innovations
When it comes to groundbreaking biotech advancements, Eric Faw Intellia is a name you might wanna keep an eye on. This article gonna dive deep into Eric Faw ...
The Globe and Mail18d
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
Intellia develops drugs with CRISPR-based therapies, pioneering in vivo therapies ... NTLA is a likely beneficiary of Eli Lilly's(NYSE: LLY) acquisition of Verve Therapeutics(NASDAQ: VERV), a ...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Insider Monkey1mon
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best CRISPR stocks to buy. Citizens JMP reaffirmed its Market Perform rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) on June 17.